Sponsor Content: ICYMI: PhRMA’s Lori Reilly and Boehringer Ingelheim’s Dan Asch weighed in on the critical role biopharmaceutical R&D plays in the discovery of novel therapies that improve outcomes for cancer patients at #PeopleVCancer. Watch the conversation here:
AtlanticLIVE’s Post
More Relevant Posts
-
Pharmaceutical innovation is transforming cancer treatment, offering new hope for patients worldwide. By investing in the fight against cancer, you're not only making a smart financial decision but also contributing to a healthier future. Learn more about how you can make an impact while supporting groundbreaking research. 🔗 https://lnkd.in/eniZsTtc Together we continue #Investing4Tomorrow #CandriamAgainstCancer #PinkOctober #HealthcareInvesting #InvestmentStrategy
To view or add a comment, sign in
-
Enhancing research efficiency is crucial for breakthrough cancer therapies. Learn how Genmab improved data access, analysis, and visualization with Certara's SEND Explorer web-based tool for non-clinical study data analysis, boosting their non-clinical drug development. Read the full case study: https://ow.ly/lOmM50TeWvz #Certara #Genmab #FutureOfPharma #PharmaceuticalInnovation #DrugDevelopment #CancerResearch #DataManagement #SENDStandards #DataDriven #Nonclinical #PharmaceuticalResearch #AntibodyDrugConjugates #ComplexToxicologyData
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare
To view or add a comment, sign in
-
BREAKING: Just hours before America's biggest cancer conference kicks off, a small biotech called Summit Therapeutics, Inc. made waves with new late-stage results. Summit's cancer drug beat Merck's flagship immunotherapy Keytruda in a Phase 3 lung cancer study conducted in China. That led to a multibillion-dollar stock move, with Summit gaining over $5 billion in market value on Thursday, while Merck's shares dropped just over 1%. It will also re-open contentious questions about the willingness of FDA regulators and US oncologists to rely on China-based clinical results. The success also boosts the chances of a rare repeat success in biotech for CEO Bob Duggan, who previously ran Pharmacyclics, an AbbVie Company, before selling it in 2015 for $21 billion and becoming a billionaire. My latest for Endpoints News:
Summit Therapeutics’ stock soars as biotech says its cancer drug beat Keytruda in Phase 3
https://endpts.com
To view or add a comment, sign in
-
From planning and logistics to regulatory approvals and patient recruitment, immuno-oncology (IO) therapies pose unique challenges in clinical research. Discover how IQVIA Biotech’s cutting-edge approach helps biotech and emerging biopharma companies to successfully navigate IO trials and advance cancer treatments. https://bit.ly/3Bk4UmT #clinicalresearch #immunooncology
To view or add a comment, sign in
-
From planning and logistics to regulatory approvals and patient recruitment, immuno-oncology (IO) therapies pose unique challenges in clinical research. Discover how IQVIA Biotech’s cutting-edge approach helps biotech and emerging biopharma companies to successfully navigate IO trials and advance cancer treatments. https://bit.ly/3wAON2t #ImmunoOncology #clinicalresearch
Top 5 Challenges for Pursuing IO Therapy Clinical Trials
To view or add a comment, sign in
-
Thoughts on this? >> AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech
AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer
https://endpts.com
To view or add a comment, sign in
-
Our #CancerResearch approach is driven by our deep understanding of causal human biology. Leveraging our differentiated research platforms, targeted #ProteinDegradation, #CellTherapy and radiopharmaceutical therapeutics (RPTs), we’re leading the way as we work to advance transformative new treatment options for patients. Explore our approach to cancer research: https://bit.ly/3Rb1R5C #ASCO24
To view or add a comment, sign in
-
We're excited to share a recent feature in e27 (Optimatic) about Albatroz Therapeutics' mission to revolutionize cancer treatment for patients with solid tumors. As highlighted in the article, we're developing therapeutic antibodies that block a key target essential for the spread of solid tumors. We're also working on novel Antibody-Drug Conjugates (ADCs) to further enhance the efficacy of our treatments in eradicating cancerous cells and transforming cancer treatment for many individuals. Follow us as we progress in our mission to bring better cancer therapies to patients worldwide. You can read the full article at the link below. #AlbatrozTherapeutics #CancerResearch #SolidTumors #TargetedTherapy #Biotech #Singapore
Albatroz Therapeutics takes aim at solid tumours, increasing hope for enhanced treatment outcomes | e27
e27.co
To view or add a comment, sign in
-
🖥️ On Tuesday 25 June we will host a special webinar tailored for oncology applications. Reserve your place today: https://ow.ly/2Li230sCFQZ Formulators and developers face a significant challenge. During this webinar, we will evaluate stability data of several small molecule drugs for cancer. Degradation and instability in chemotherapeutics can lead to: ▶️ Extended development timelines ▶️ Regulatory challenges ▶️ Compromised product efficacy. This ultimately delays lifesaving treatments for those who need it most - the patients. We will show you how we can optimise oncological drug delivery resulting in long-term formulation stability, extended drug shelf life, and ultimately improved drug performance and efficacy. Reserve your place today for a morning of learning!
To view or add a comment, sign in
1,800 followers